Annovis Bio (ANVS) Expected to Announce Earnings on Wednesday

Key Points

• Annovis Bio (ANVS) is set to report its Q2 2025 earnings on August 13th, with an expected loss of ($0.36) per share for the quarter.
• The company recently reported a narrower loss of ($0.32) EPS, surpassing the consensus estimate of ($0.47) in its previous earnings announcement.
• Analysts have reduced price targets for Annovis Bio, with a current consensus rating of "Buy" and an average price target of $18.00.

Annovis Bio (NYSE:ANVS - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect Annovis Bio to post earnings of ($0.36) per share for the quarter.

Annovis Bio (NYSE:ANVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Performance

Shares of NYSE ANVS traded down $0.04 during midday trading on Friday, hitting $2.56. 163,521 shares of the company's stock traded hands, compared to its average volume of 287,986. The stock has a market capitalization of $49.87 million, a price-to-earnings ratio of -1.18 and a beta of 1.51. The firm has a fifty day moving average of $2.68 and a 200 day moving average of $2.28. Annovis Bio has a 1 year low of $1.11 and a 1 year high of $10.54.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ANVS. HC Wainwright dropped their price target on shares of Annovis Bio from $30.00 to $12.00 and set a "buy" rating on the stock in a research note on Monday, June 9th. Canaccord Genuity Group decreased their target price on Annovis Bio from $26.00 to $17.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Annovis Bio presently has an average rating of "Buy" and a consensus target price of $18.00.

Hedge Funds Weigh In On Annovis Bio

A hedge fund recently raised its stake in Annovis Bio stock. Geode Capital Management LLC lifted its position in shares of Annovis Bio, Inc. (NYSE:ANVS - Free Report) by 20.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 183,287 shares of the company's stock after buying an additional 30,674 shares during the quarter. Geode Capital Management LLC owned approximately 0.94% of Annovis Bio worth $398,000 at the end of the most recent quarter. 15.83% of the stock is currently owned by hedge funds and other institutional investors.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.